Representatives of Scotland’s ATMP industry get input into new CGT Catapult Edinburgh facility

The Cell and Gene Therapy Catapult (CGT Catapult) recently (23rd June) held a small event in the University of Edinburgh’s Institute for Regeneration and Repair, right in the heart of the Edinburgh BioQuarter.

The event highlighted the strengths of the advanced therapy medicinal product (ATMP) ecosystem in the north of the UK and included an afternoon of talks from CGT Catapult’s Chief Executive, Matthew Durdy, Professor Stuart Forbes of the University of Edinburgh and Dr Josef Christensen of Novo Nordisk.

The Edinburgh facility will grow ATMP translational expertise in the north of the UK, enabling technology and manufacturing development and clinical trial acceleration, to drive company formation and spin-out for the sector in Scotland and the North of England.

CGT Catapult is committed to realizing potential wherever it is in the UK, and to ensuring that every region can enjoy the economic and scientific benefits of this. Last week’s event was a valuable opportunity for us to engage with cell and gene therapy experts from academia, industry and the NHS in Scotland and the North of England ahead of our formal opening next year. We would particularly like to thank Professor Forbes and the Institute for Regeneration and Repair for hosting and supporting us. We’re looking forward to working closely with all of those who attended and others in the months to come.

Matthew Durdy, Chief Executive Officer, CGT Catapult

We are delighted to host CGTC at BioQuarter. There is great expertise in advanced therapies locally and regionally and I think the time is right for this strategic co-location to capitalize on this excellent science and accelerate the development of advanced therapies for the treatment of human diseases.

Stuart Forbes. Director of the Institute for Regeneration and Repair

The new CGT Catapult manufacturing development laboratories, based in the Institute for Regeneration and Repair, will formally open in early 2023.

If you wish to learn more about our capabilities please click here to view how we work